Literature DB >> 28798824

Taking it to the HILT: High-intensity local treatment with radical cystectomy for metastatic bladder cancer.

Adrian S Fairey1, Niels-Erik Jacobsen1.   

Abstract

Entities:  

Year:  2017        PMID： 28798824      PMCID： PMC5542831          DOI： 10.5489/cuaj.4800

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  10 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

Review 2.  Definitive Management of Primary Bladder Tumors in the Context of Metastatic Disease: Who, How, When, and Why?

Authors:  Matthew D Galsky; Josep Domingo-Domenech; John P Sfakianos; Bart S Ferket
Journal:  J Clin Oncol       Date:  2016-10-10       Impact factor: 44.544

3.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.

Authors:  Thomas Powles; Joseph Paul Eder; Gregg D Fine; Fadi S Braiteh; Yohann Loriot; Cristina Cruz; Joaquim Bellmunt; Howard A Burris; Daniel P Petrylak; Siew-leng Teng; Xiaodong Shen; Zachary Boyd; Priti S Hegde; Daniel S Chen; Nicholas J Vogelzang
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

4.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Authors:  G H Mickisch; A Garin; H van Poppel; L de Prijck; R Sylvester
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

5.  A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy.

Authors:  Kamran Zargar-Shoshtari; Homayoun Zargar; Yair Lotan; Jay B Shah; Bas W van Rhijn; Siamak Daneshmand; Philippe E Spiess; Peter C Black
Journal:  J Urol       Date:  2015-07-21       Impact factor: 7.450

6.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

Authors:  P J Loehrer; L H Einhorn; P J Elson; E D Crawford; P Kuebler; I Tannock; D Raghavan; R Stuart-Harris; M F Sarosdy; B A Lowe
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

Review 7.  Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.

Authors:  Maud Rijnders; Ronald de Wit; Joost L Boormans; Martijn P J Lolkema; Astrid A M van der Veldt
Journal:  Eur Urol       Date:  2017-06-20       Impact factor: 20.096

8.  Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.

Authors:  Stephen H Culp; Paul F Schellhammer; Michael B Williams
Journal:  Eur Urol       Date:  2013-11-20       Impact factor: 20.096

9.  Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base.

Authors:  Thomas Seisen; Maxine Sun; Jeffrey J Leow; Mark A Preston; Alexander P Cole; Francisco Gelpi-Hammerschmidt; Nawar Hanna; Christian P Meyer; Adam S Kibel; Stuart R Lipsitz; Paul L Nguyen; Joaquim Bellmunt; Toni K Choueiri; Quoc-Dien Trinh
Journal:  J Clin Oncol       Date:  2016-10-10       Impact factor: 44.544

10.  Comprehensive molecular characterization of urothelial bladder carcinoma.

Authors: 
Journal:  Nature       Date:  2014-01-29       Impact factor: 49.962
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.